164 related articles for article (PubMed ID: 38527259)
1. Metastatic Melanoma Treatment in Special Populations.
Miceli M; Boatwright C; Mehnert JM
Cancer J; 2024 Mar-Apr 01; 30(2):71-78. PubMed ID: 38527259
[TBL] [Abstract][Full Text] [Related]
2. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
3. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
[TBL] [Abstract][Full Text] [Related]
4. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
Front Immunol; 2021; 12():661737. PubMed ID: 34025662
[TBL] [Abstract][Full Text] [Related]
6. Advanced Melanoma: Resistance Mechanisms to Current Therapies.
Haugh AM; Salama AKS; Johnson DB
Hematol Oncol Clin North Am; 2021 Feb; 35(1):111-128. PubMed ID: 33759769
[TBL] [Abstract][Full Text] [Related]
7. Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies.
Dixon-Douglas JR; Patel RP; Somasundram PM; McArthur GA
Curr Oncol Rep; 2022 Aug; 24(8):1071-1079. PubMed ID: 35366166
[TBL] [Abstract][Full Text] [Related]
8. A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.
Awada G; Schwarze JK; Tijtgat J; Fasolino G; Kruse V; Neyns B
Melanoma Res; 2022 Jun; 32(3):183-191. PubMed ID: 35377866
[TBL] [Abstract][Full Text] [Related]
9. Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
Haist M; Stege H; Kuske M; Bauer J; Klumpp A; Grabbe S; Bros M
Cancer Metastasis Rev; 2023 Jun; 42(2):481-505. PubMed ID: 37022618
[TBL] [Abstract][Full Text] [Related]
10. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
[TBL] [Abstract][Full Text] [Related]
11. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
12. What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?
Hadfield MJ; Sullivan RJ
Cancer J; 2024 Mar-Apr 01; 30(2):84-91. PubMed ID: 38527261
[TBL] [Abstract][Full Text] [Related]
13. Optimal strategy in managing advanced melanoma.
Uchi H
J Dermatol; 2024 Mar; 51(3):324-334. PubMed ID: 38087810
[TBL] [Abstract][Full Text] [Related]
14. First line treatment of BRAF mutated advanced melanoma: Does one size fit all?
Giugliano F; Crimini E; Tarantino P; Zagami P; Uliano J; Corti C; Trapani D; Curigliano G; Ascierto PA
Cancer Treat Rev; 2021 Sep; 99():102253. PubMed ID: 34186441
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma.
Kim DY; Swetter SM; Huhmann L; Dizon MP; Ferguson JM; Osborne TF; Spence AC; Ziad A; Fillmore N; Hartman RI
J Am Acad Dermatol; 2024 Mar; 90(3):620-623. PubMed ID: 37924953
[No Abstract] [Full Text] [Related]
16. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
[TBL] [Abstract][Full Text] [Related]
17. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.
Broman KK; Dossett LA; Sun J; Eroglu Z; Zager JS
Expert Opin Drug Saf; 2019 May; 18(5):381-392. PubMed ID: 30977681
[TBL] [Abstract][Full Text] [Related]
18. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
Schummer P; Schilling B; Gesierich A
Am J Clin Dermatol; 2020 Aug; 21(4):493-504. PubMed ID: 32124332
[TBL] [Abstract][Full Text] [Related]
20. Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients.
Ferrucci PF; Lens M; Cocorocchio E
Curr Oncol Rep; 2021 Nov; 23(12):138. PubMed ID: 34735635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]